-
1
-
-
0020617013
-
Increased plasma arginine vasopressin levels in patients with congestive heart failure
-
Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN. Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol. 1983;1:1385-1390.
-
(1983)
J Am Coll Cardiol
, vol.1
, pp. 1385-1390
-
-
Goldsmith, S.R.1
Francis, G.S.2
Cowley Jr., A.W.3
Levine, T.B.4
Cohn, J.N.5
-
2
-
-
33947713810
-
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial
-
Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. J Am Med Assoc. 2007;297: 1319-1331.
-
(2007)
J Am Med Assoc
, vol.297
, pp. 1319-1331
-
-
Konstam, M.A.1
Gheorghiade, M.2
Burnett Jr., J.C.3
Grinfeld, L.4
Maggioni, A.P.5
Swedberg, K.6
Udelson, J.E.7
Zannad, F.8
Cook, T.9
Ouyang, J.10
Zimmer, C.11
Orlandi, C.12
-
3
-
-
33947719178
-
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials
-
Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. J Am Med Assoc. 2007;297:1332-1343.
-
(2007)
J Am Med Assoc
, vol.297
, pp. 1332-1343
-
-
Gheorghiade, M.1
Konstam, M.A.2
Burnett Jr., J.C.3
Grinfeld, L.4
Maggioni, A.P.5
Swedberg, K.6
Udelson, J.E.7
Zannad, F.8
Cook, T.9
Ouyang, J.10
Zimmer, C.11
Orlandi, C.12
-
4
-
-
0037181511
-
Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial
-
Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. J Am Med Assoc. 2002;287:1531-1540.
-
(2002)
J Am Med Assoc
, vol.287
, pp. 1531-1540
-
-
-
5
-
-
17144392493
-
Short-term risk of death after treatment with nesiritide for decompensated heart failure: A pooled analysis of randomized controlled trials
-
Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. J Am Med Assoc. 2005; 293:1900-1905.
-
(2005)
J Am Med Assoc
, vol.293
, pp. 1900-1905
-
-
Sackner-Bernstein, J.D.1
Kowalski, M.2
Fox, M.3
Aaronson, K.4
-
6
-
-
16344377117
-
Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure
-
Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491.
-
(2005)
Circulation
, vol.111
, pp. 1487-1491
-
-
Sackner-Bernstein, J.D.1
Skopicki, H.A.2
Aaronson, K.D.3
-
7
-
-
34748837363
-
Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: A double-blind placebo-controlled pilot study
-
Chen HH, Sundt TM, Cook DJ, Heublein DM, Burnett JC Jr. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation. 2007;116:I134-I138.
-
(2007)
Circulation
, vol.116
-
-
Chen, H.H.1
Sundt, T.M.2
Cook, D.J.3
Heublein, D.M.4
Burnett Jr., J.C.5
-
8
-
-
28444443740
-
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure
-
Hawkridge AM, Heublein DM, Bergen HR III, Cataliotti A, Burnett JC Jr, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci U S A. 2005;102:17442-17447.
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, pp. 17442-17447
-
-
Hawkridge, A.M.1
Heublein, D.M.2
Bergen Iii, H.R.3
Cataliotti, A.4
Burnett Jr., J.C.5
Muddiman, D.C.6
-
9
-
-
63849103296
-
Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure
-
Niederkofler E, Kiernan U, O'Rear J, Menon S, Saghir S, Protter A, Nelson R, Schellenberger U. Detection of endogenous B-type natriuretic peptide at very low concentrations in patients with heart failure. Circ Heart Fail. 2008;1:258-264.
-
(2008)
Circ Heart Fail
, vol.1
, pp. 258-264
-
-
Niederkofler, E.1
Kiernan, U.2
O'rear, J.3
Menon, S.4
Saghir, S.5
Protter, A.6
Nelson, R.7
Schellenberger, U.8
-
10
-
-
0035045833
-
Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure
-
Lisy O, Lainchbury JG, Leskinen H, Burnett JC Jr. Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension. 2001;37:1089-1094.
-
(2001)
Hypertension
, vol.37
, pp. 1089-1094
-
-
Lisy, O.1
Lainchbury, J.G.2
Leskinen, H.3
Burnett Jr., J.C.4
-
11
-
-
0032805710
-
Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure
-
Chen HH, Schirger JA, Chau WL, Jougasaki M, Lisy O, Redfield MM, Barclay PT, Burnett JC Jr. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation. 1999;100:2443-2448.
-
(1999)
Circulation
, vol.100
, pp. 2443-2448
-
-
Chen, H.H.1
Schirger, J.A.2
Chau, W.L.3
Jougasaki, M.4
Lisy, O.5
Redfield, M.M.6
Barclay, P.T.7
Burnett Jr., J.C.8
-
12
-
-
1842612047
-
Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemideinduced aldosterone activation in experimental heart failure
-
Cataliotti A, Boerrigter G, Costello-Boerrigter LC, Schirger JA, Tsuruda T, Heublein DM, Chen HH, Malatino LS, Burnett JC Jr. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemideinduced aldosterone activation in experimental heart failure. Circulation. 2004;109:1680-1685.
-
(2004)
Circulation
, vol.109
, pp. 1680-1685
-
-
Cataliotti, A.1
Boerrigter, G.2
Costello-Boerrigter, L.C.3
Schirger, J.A.4
Tsuruda, T.5
Heublein, D.M.6
Chen, H.H.7
Malatino, L.S.8
Burnett Jr., J.C.9
-
13
-
-
33846794760
-
Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation
-
Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett JC Jr. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol. 2007;292:R897-R901.
-
(2007)
Am J Physiol Regul Integr Comp Physiol
, vol.292
-
-
Boerrigter, G.1
Costello-Boerrigter, L.C.2
Harty, G.J.3
Lapp, H.4
Burnett Jr., J.C.5
-
14
-
-
0012140265
-
Eine einfache colorimetrische Methode zur Inulinbestimmung fuer Nieren-Clearance-Untersuchungen bei Stoffwechselgesunden und Diabetikern
-
Fuhr J, Kaczmarczyk K, Kruttgen C. Eine einfache colorimetrische Methode zur Inulinbestimmung fuer Nieren-Clearance-Untersuchungen bei Stoffwechselgesunden und Diabetikern. Klin Wochenschr. 1955;33: 729-733.
-
(1955)
Klin Wochenschr
, vol.33
, pp. 729-733
-
-
Fuhr, J.1
Kaczmarczyk, K.2
Kruttgen, C.3
-
15
-
-
0022468421
-
Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMPmediated process
-
Kurtz A, Della Bruna R, Pfeilschifter J, Taugner R, Bauer C. Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMPmediated process. Proc Natl Acad Sci U S A. 1986;83:4769-4773.
-
(1986)
Proc Natl Acad Sci U S A
, vol.83
, pp. 4769-4773
-
-
Kurtz, A.1
Della Bruna, R.2
Pfeilschifter, J.3
Taugner, R.4
Bauer, C.5
-
16
-
-
0030338446
-
Natriuretic peptides in the treatment of heart failure
-
Yasue H, Yoshimura M. Natriuretic peptides in the treatment of heart failure. J Card Fail. 1996;2:S277-S285.
-
(1996)
J Card Fail
, vol.2
-
-
Yasue, H.1
Yoshimura, M.2
-
17
-
-
0022634214
-
Alpha-human atrial natriuretic polypeptide inhibits steroidogenesis in cultured human adrenal cells
-
Higuchi K, Nawata H, Kato K, Ibayashi H, Matsuo H. Alpha-human atrial natriuretic polypeptide inhibits steroidogenesis in cultured human adrenal cells. J Clin Endocrinol Metab. 1986;62:941-944.
-
(1986)
J Clin Endocrinol Metab
, vol.62
, pp. 941-944
-
-
Higuchi, K.1
Nawata, H.2
Kato, K.3
Ibayashi, H.4
Matsuo, H.5
-
18
-
-
0025611653
-
Effects of atrial natriuretic peptide on renal arterioles: Morphometric analysis using microvascular casts
-
Kimura K, Hirata Y, Nanba S, Tojo A, Matsuoka H, Sugimoto T. Effects of atrial natriuretic peptide on renal arterioles: morphometric analysis using microvascular casts. Am J Physiol. 1990;259:F936-F944.
-
(1990)
Am J Physiol
, vol.259
-
-
Kimura, K.1
Hirata, Y.2
Nanba, S.3
Tojo, A.4
Matsuoka, H.5
Sugimoto, T.6
-
19
-
-
69449099378
-
Atrial natriuretic peptide and nitric oxide signaling antagonizes vasopressin-mediated water permeability in inner medullary collecting duct cells
-
Klokkers J, Langehanenberg P, Kemper B, Kosmeier S, von Bally G, Riethmuller C, Wunder F, Sindic A, Pavenstadt H, Schlatter E, Edemir B. Atrial natriuretic peptide and nitric oxide signaling antagonizes vasopressin-mediated water permeability in inner medullary collecting duct cells. Am J Physiol Renal Physiol. 2009;297:F693-F703.
-
(2009)
Am J Physiol Renal Physiol
, vol.297
-
-
Klokkers, J.1
Langehanenberg, P.2
Kemper, B.3
Kosmeier, S.4
Von Bally, G.5
Riethmuller, C.6
Wunder, F.7
Sindic, A.8
Pavenstadt, H.9
Schlatter, E.10
Edemir, B.11
-
20
-
-
0023276509
-
Untreated heart failure: Clinical and neuroendocrine effects of introducing diuretics
-
Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17-22.
-
(1987)
Br Heart J
, vol.57
, pp. 17-22
-
-
Bayliss, J.1
Norell, M.2
Canepa-Anson, R.3
Sutton, G.4
Poole-Wilson, P.5
-
21
-
-
0025153828
-
Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)
-
Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729.
-
(1990)
Circulation
, vol.82
, pp. 1724-1729
-
-
Francis, G.S.1
Benedict, C.2
Johnstone, D.E.3
Kirlin, P.C.4
Nicklas, J.5
Liang, C.S.6
Kubo, S.H.7
Rudin-Toretsky, E.8
Yusuf, S.9
-
22
-
-
0037133628
-
BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy
-
Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348-1353.
-
(2002)
Circulation
, vol.105
, pp. 1348-1353
-
-
Gottlieb, S.S.1
Brater, D.C.2
Thomas, I.3
Havranek, E.4
Bourge, R.5
Goldman, S.6
Dyer, F.7
Gomez, M.8
Bennett, D.9
Ticho, B.10
Beckman, E.11
Abraham, W.T.12
-
23
-
-
33644867235
-
Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure
-
Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC Jr. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:F273-F278.
-
(2006)
Am J Physiol Renal Physiol
, vol.290
-
-
Costello-Boerrigter, L.C.1
Smith, W.B.2
Boerrigter, G.3
Ouyang, J.4
Zimmer, C.A.5
Orlandi, C.6
Burnett Jr., J.C.7
-
24
-
-
34249036412
-
Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor
-
Birumachi J, Hiroyama M, Fujiwara Y, Aoyagi T, Sanbe A, Tanoue A. Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor. Eur J Pharmacol. 2007;566:226-230.
-
(2007)
Eur J Pharmacol
, vol.566
, pp. 226-230
-
-
Birumachi, J.1
Hiroyama, M.2
Fujiwara, Y.3
Aoyagi, T.4
Sanbe, A.5
Tanoue, A.6
-
25
-
-
49949111488
-
Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells
-
Aoyagi T, Izumi Y, Hiroyama M, Matsuzaki T, Yasuoka Y, Sanbe A, Miyazaki H, Fujiwara Y, Nakayama Y, Kohda Y, Yamauchi J, Inoue T, Kawahara K, Saito H, Tomita K, Nonoguchi H, Tanoue A. Vasopressin regulates the renin-angiotensin- aldosterone system via V1a receptors in macula densa cells. Am J Physiol Renal Physiol. 2008;295:F100-F107.
-
(2008)
Am J Physiol Renal Physiol
, vol.295
-
-
Aoyagi, T.1
Izumi, Y.2
Hiroyama, M.3
Matsuzaki, T.4
Yasuoka, Y.5
Sanbe, A.6
Miyazaki, H.7
Fujiwara, Y.8
Nakayama, Y.9
Kohda, Y.10
Yamauchi, J.11
Inoue, T.12
Kawahara, K.13
Saito, H.14
Tomita, K.15
Nonoguchi, H.16
Tanoue, A.17
-
26
-
-
54349103474
-
Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: An international, multicenter, randomized, placebocontrolled trial
-
Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, Haught WH, Meymandi S, Macarie C, Raef D, Wedge P, Konstam MA, Gheorghiade M. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebocontrolled trial. J Am Coll Cardiol. 2008;52:1540-1545.
-
(2008)
J Am Coll Cardiol
, vol.52
, pp. 1540-1545
-
-
Udelson, J.E.1
Orlandi, C.2
Ouyang, J.3
Krasa, H.4
Zimmer, C.A.5
Frivold, G.6
Haught, W.H.7
Meymandi, S.8
MacArie, C.9
Raef, D.10
Wedge, P.11
Konstam, M.A.12
Gheorghiade, M.13
-
27
-
-
33644860438
-
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure
-
Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671-678.
-
(2006)
Circulation
, vol.113
, pp. 671-678
-
-
Hillege, H.L.1
Nitsch, D.2
Pfeffer, M.A.3
Swedberg, K.4
McMurray, J.J.5
Yusuf, S.6
Granger, C.B.7
Michelson, E.L.8
Ostergren, J.9
Cornel, J.H.10
De Zeeuw, D.11
Pocock, S.12
Van Veldhuisen, D.J.13
-
28
-
-
0034163914
-
The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction
-
Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681-689.
-
(2000)
J Am Coll Cardiol
, vol.35
, pp. 681-689
-
-
Dries, D.L.1
Exner, D.V.2
Domanski, M.J.3
Greenberg, B.4
Stevenson, L.W.5
-
29
-
-
0037145913
-
Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure
-
Kearney MT, Fox KA, Lee AJ, Prescott RJ, Shah AM, Batin PD, Baig W, Lindsay S, Callahan TS, Shell WE, Eckberg DL, Zaman AG, Williams S, Neilson JM, Nolan J. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J Am Coll Cardiol. 2002;40:1801-1808.
-
(2002)
J Am Coll Cardiol
, vol.40
, pp. 1801-1808
-
-
Kearney, M.T.1
Fox, K.A.2
Lee, A.J.3
Prescott, R.J.4
Shah, A.M.5
Batin, P.D.6
Baig, W.7
Lindsay, S.8
Callahan, T.S.9
Shell, W.E.10
Eckberg, D.L.11
Zaman, A.G.12
Williams, S.13
Neilson, J.M.14
Nolan, J.15
-
30
-
-
18844423537
-
Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study
-
Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Pina IL, Felker GM, Adams KF Jr, Califf RM, Gheorghiade M. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005;111:2454-2460.
-
(2005)
Circulation
, vol.111
, pp. 2454-2460
-
-
Klein, L.1
O'connor, C.M.2
Leimberger, J.D.3
Gattis-Stough, W.4
Pina, I.L.5
Felker, G.M.6
Adams Jr., K.F.7
Califf, R.M.8
Gheorghiade, M.9
-
31
-
-
34548348725
-
Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: An analysis from the OPTIMIZE-HF registry
-
Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O'Connor CM, She L, Yancy CW, Young J, Fonarow GC. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28:980-988.
-
(2007)
Eur Heart J
, vol.28
, pp. 980-988
-
-
Gheorghiade, M.1
Abraham, W.T.2
Albert, N.M.3
Gattis Stough, W.4
Greenberg, B.H.5
O'connor, C.M.6
She, L.7
Yancy, C.W.8
Young, J.9
Fonarow, G.C.10
-
32
-
-
33846844802
-
Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: The NAPA Trial
-
Mentzer RM Jr, Oz MC, Sladen RN, Graeve AH, Hebeler RF Jr, Luber JM Jr, Smedira NG. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. J Am Coll Cardiol. 2007;49:716-726.
-
(2007)
J Am Coll Cardiol
, vol.49
, pp. 716-726
-
-
Mentzer Jr., R.M.1
Oz, M.C.2
Sladen, R.N.3
Graeve, A.H.4
Hebeler Jr., R.F.5
Luber Jr., J.M.6
Smedira, N.G.7
-
33
-
-
20844454740
-
Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine
-
Wang DJ, Dowling TC, Meadows D, Ayala T, Marshall J, Minshall S, Greenberg N, Thattassery E, Fisher ML, Rao K, Gottlieb SS. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004;110:1620-1625.
-
(2004)
Circulation
, vol.110
, pp. 1620-1625
-
-
Wang, D.J.1
Dowling, T.C.2
Meadows, D.3
Ayala, T.4
Marshall, J.5
Minshall, S.6
Greenberg, N.7
Thattassery, E.8
Fisher, M.L.9
Rao, K.10
Gottlieb, S.S.11
|